NYSE American - Delayed Quote • USD
Armata Pharmaceuticals, Inc. (ARMP)
At close: April 26 at 3:56 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 2 | 2 | 2 | 2 |
| Avg. Estimate | -0.31 | -0.32 | -1.33 | -1.3 |
| Low Estimate | -0.34 | -0.35 | -1.43 | -1.31 |
| High Estimate | -0.28 | -0.29 | -1.24 | -1.29 |
| Year Ago EPS | -0.4 | -0.1 | -1.91 | -1.33 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 2 | 2 | 2 | 2 |
| Avg. Estimate | 1.1M | 1.15M | 4.65M | 2.75M |
| Low Estimate | 1M | 1.1M | 4.5M | -- |
| High Estimate | 1.2M | 1.2M | 4.8M | 5.5M |
| Year Ago Sales | 796k | 980k | 4.53M | 4.65M |
| Sales Growth (year/est) | 38.20% | 17.30% | 2.70% | -40.90% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -0.32 | -0.37 | -0.31 | -0.35 |
| EPS Actual | -0.4 | -0.1 | -0.86 | -0.55 |
| Difference | -0.08 | 0.27 | -0.55 | -0.2 |
| Surprise % | -25.00% | 73.00% | -177.40% | -57.10% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.31 | -0.32 | -1.33 | -1.3 |
| 7 Days Ago | -0.31 | -0.32 | -1.33 | -1.3 |
| 30 Days Ago | -0.31 | -0.32 | -1.33 | -1.3 |
| 60 Days Ago | -0.24 | -0.25 | -0.88 | -0.66 |
| 90 Days Ago | -0.24 | -0.25 | -0.88 | -0.66 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | ARMP | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 22.50% | -- | -- | 6.50% |
| Next Qtr. | -220.00% | -- | -- | 12.00% |
| Current Year | 30.40% | -- | -- | 5.30% |
| Next Year | 2.30% | -- | -- | 13.10% |
| Next 5 Years (per annum) | -- | -- | -- | 11.09% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Maintains | HC Wainwright & Co.: Buy to Buy | 3/22/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 8/14/2023 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 5/12/2023 |
| Reiterates | HC Wainwright & Co.: Buy | 3/17/2023 |
| Reiterates | HC Wainwright & Co.: Buy | 3/7/2023 |
| Maintains | HC Wainwright & Co.: Buy | 3/22/2021 |
Related Tickers
INVA Innoviva, Inc.
15.26
+1.80%
PHGE BiomX Inc.
0.3500
+4.17%
SYBX Synlogic, Inc.
1.8700
-1.06%
GNFT Genfit S.A.
3.4900
+2.35%
ELDN Eledon Pharmaceuticals, Inc.
2.0600
+1.98%
ANTX AN2 Therapeutics, Inc.
2.3200
+1.75%
ARDS Aridis Pharmaceuticals, Inc.
0.0650
0.00%
TRVI Trevi Therapeutics, Inc.
2.7800
+9.45%
AEON AEON Biopharma, Inc.
5.07
+19.29%
IPSC Century Therapeutics, Inc.
2.8800
-8.57%